Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2023 Oct 2;13:16519. doi: 10.1038/s41598-023-38888-y

HCG supplement did not accelerate tunica albuginea remodeling to facilitate penile growth

Tao Li 1,2,#, Yuan Tian 2,#, Quliang Zhong 2, Peng Chen 2, Junhao Zhang 2, Guangshi Du 3, Lei Li 4, Yiting Jiang 5,✉, Kehua Jiang 1,✉
PMCID: PMC10545796  PMID: 37783699

Abstract

Penile size is closely concerned and short penis contributes serious sexual dysfunction and tremendous psychological problems to couples. Androgen is essential for penile development and testosterone replacement is recommended to patients with micropenis. We previously proved that inhibiting activity of lysyl oxidase (Anti-lysyl oxidase, Anti-LOX) combined with vacuum erectile device (VED) lengthened penis by remodeling tunica albuginea. We thus explored whether HCG supplement could accelerate tunica albuginea remodeling (induced by Anti-LOX + VED) to promote penile growth. Forty-two SD male rats (4 weeks old) were purchased and divided into 7 groups: control, Anti-LOX, HCG, VED (with a negative aspirated pressure of − 300 mmHg), Anti-LOX + VED, HCG + VED, and Anti-LOX + HCG + VED. After an intervention for 4 weeks, all rats’ penile length, exposed penile length, and erectile function were measured. Serum samples were collected to detect hormone levels and penile corpus cavernosum were harvested for histo-pathological analysis. All intervention groups showed significantly longer penis than controlled rats. Anti-LOX sharply increased penile length and exposed length by 15% and 9% respectively, this lengthening effect was more obvious in Anti-LOX + VED group (26% and 19%, respectively). Although HCG promoted penile length by 8%, this effect was slight for exposed length (3%). Moreover, Anti-LOX + HCG + VED dramatically increased penile length and exposed length by 22% and 18%, respectively, which was similar with that in Anti-LOX + VED (26% and 19%, respectively). HCG dramatically stimulated testosterone and dihydrotestosterone secretions than control group, whether with or without Anti-LOX and VED; while it induced more AR expression than other groups. Finally, all procedures did not improve or deteriorate normal erectile function. Although we verified that Anti-LOX + VED lengthened penis by inducing tunica albuginea remodeling, however, HCG supplement did not synergize with Anti-LOX + VED to accelerate albuginea remodeling to facilitate penile growth.

Subject terms: Diseases, Urology

Introduction

As an essential male reproductive organ and indicator for sexual development, penis was a symbol of strength and masculinity throughout human history1–3. Short penis which refers micropenis (normally formed but stretched length < 2.5 SD of normal median, like < 7.5 cm for adult men) or acquired penile retraction (Peyronie’s disease, post-trauma, post-infection, and post-priapism)4–9 has contributed various psychological problems3,4 and affected the sexual quality of life, fear of sexual relationship, premature ejaculation (PE), as well as impotence10,11. These patients always have strong desire to possess a larger penis to satisfy partners or just improve self-esteem1,3, which present considerable challenges for urologists/plastic surgeons9,12.

Currently, numerous techniques and methods have been recommended to lengthen or enlarge penis. However, the widely advertised non-invasive techniques like penile extender, penoscrotal rings, and botulinum toxin are limited by insufficient scientific evidence6. The invasive phalloplasties like inverted V–Y plasty closure, penile suspensory ligament division, and venous grafing for the corpora cavernosa remain controversial6 and experimental1,5, considering the lengthening effect is unclear and the surgical method or indication is poorly standard5,6. Even though, more than 10 000 males received penile lengthening surgery in US during 1991–19981. Recently, more individuals with a normal penile size also consult to enlarge penis just for aesthetic reasons1,4. Although a suitable psychotherapy to convince they have a normal size is the best solution1,9, some authors has recommended penile lengthening as an aesthetic plastic surgery rather than just reconstructive operation, considering the huge potential population4. Therefore, more explorations to lengthen penis are necessary, except intensive psychosexual counselling.

Penile size during tumescence is determined by tunica albuginea which mainly composed by abundant thick collagen bundles and ample elastic fibers13,14. We previously found that inhibiting activity of lysyl oxidase (Anti-lysyl oxidase, Anti-LOX) remodeled tunica albuginea by reducing collagen crosslinking to increase penile length by 10.8% for adult rats, while a vacuum erectile device (VED) force induced collagen realignment to lengthen penis by 8.2%15. Moreover, Anti-LOX combined with VED (Anti-LOX + VED) contributed more remarkable albugineas remodeling and lengthened penis by 17.4% for adult rats15 and 19.84% for pubertal rats16.

Human penile development is closely dependent on androgen, especially during the third periods of late gestation, first 4 years after birth, and puberty17–19. Penile growth is relatively slow after birth but reaches a peak from 12 to 16 years, which is coinciding with the spurt of testicular development and testosterone secretion15,20. Although remained some controversy, testosterone replacement has been recommended for patients with congenital micropenis9,12,15,19,21,22. Considering its crucial role in regulating penile growth, we wondered whether HCG (FDA approved testosterone releasing agent without impairing spermatogenesis23) supplement could synergize with Anti-LOX + VED to accelerate tunica albugineas remodeling, and finally promote penile length.

Material and methods

This study was approved by Animal Ethics Committee of Guizhou Provincial People’s Hospital (No. 2020064), Guiyang, China. All rats were housed under standard guidelines, while all methods were carried out in accordance with relevant regulations and ARRIVE guidelines. Forty-two Sprague–Dawley male rats (4 weeks old, about 130 g) were purchased (Dashuo Experimental Animal, Co Ltd, Chengdu, Sichuan Procince, China) and randomly divided into 7 groups (6 rats for each group) after adaptive feeding for 3 days, including groups of control (gavaged with saline), Anti-LOX, HCG (human chorionic gonadotropin), VED, Anti-LOX + VED, HCG + VED, and Anti-LOX + HCG + VED.

Anti-LOX was applied by intragastric gavaged with a specific LOX inhibitor, β-aminopropionitrile (BAPN) fumarate (Shanghai Aladdin Biochemical Technology Co., Ltd., Shanghai, China) with a dose of 100 mg/kg/d15,16,24,25. HCG was intramuscularly administrated using a standard protocol of 100 IU/kg (3 times per week)26–28. VED meant the penis was stretched by a VED force with a negative aspiration pressure of -300 mmHg (Chengdu Xin Wei Cheng Technology Co., Ltd., Chengdu, China), the procedure was performed twice daily (each session lasting 5-min, with a 2-min interval) from Monday to Friday15,16,29. VED aspiration was ceased for 1 or 2 days when prepuce bleed was serious. In addition, groups with VED procedure were performed under isoflurane anesthesia, thus all the other groups including control were also anesthetized. The total intervention duration last for 4 weeks before the rats were used for the following analysis.

Penile length measurement

On the last intervention day, rat’s penile length was measured after body weight was recorded. As described previously15,16,30, the injection end of a modified 2.5 mL disposable syringe was connected to VED device (Chengdu Xin Wei Cheng Technology Co., Ltd., Chengdu, China), the other side of syringe was placed over penis and tightly pressed to the pubis. After a unified aspirated precession (− 300 mmHg of 5 min for twice, with a 2 min interval), stretched penile length was read and recorded as a ruler close to the syringe flanged end.

Erectile function assessment

After a 1-week washout period since penile length measurement, the erectile function was assessed as previously described15,16,31–33. Briefly, rat was anesthetized by isoflurane, then the cavernous never, penile crus, and carotid were successively exposed or isolated. As the cavernous never was electrically stimulated (5 V, 20 Hz, pulse width of 5.0 ms, for 50 s), the intracavernous pressure (ICP) in penile crus and mean arterial pressure (MAP) in carotid were simultaneously monitored by a BL420 biofunctional experiment system (TME Technology Co. Ltd. Chengdu, China). The maximum ICP/ MAP ratio was recorded and analyzed.

Exposed penile length measurement

Exposed penile length was recorded after erectile function assessment. Briefly, the penis was completely exposed and vertically stretched with the tip of glans cartilage clipped by vessel forceps, until rat’s back/rump leave animal experimental table. Exposed penile length was measured from the junction of urethral bulb and corpus cavernosum to the tip of glans cartilage15.

Arterial blood was then collected from carotid artery for hormone detection, while the corpus cavernosum was washed with cold phosphate buffered saline (PBS) and cut into two sections (proximal and distal) for further analysis.

Hormone detection

Arterial blood was clotted at room temperature for 2 h and centrifuged for serum (then immediately stored at − 80 °C). Serum samples were used to detect levels of HCG (Shanghai Enzyme-linked Biotechnology Co., Ltd), testosterone (E-EL-0155c; Elabscience Biotechnology Co. Ltd), and dihydrotestosterone (CSB-E07879r; CUSABIO BIOTECH CO., Ltd) by enzyme linked immunosorbent assay (ELISA) kits according to manufacturer’s instructions. The final density of each sample was determined by a microplate reader (450) nm, and hormone concentrations were calculated according affiliated standard curve.

Western blot

The distal corpus cavernosum was snipped and homogenized in radio immunoprecipitation assay (RIPA) lysis buffer, and then centrifuged at 12000g for 20 min at 4 °C. The supernatant was collected and protein concentration was determined by Coomassie brilliant blue G-250 working buffer. Equal amount protein was loaded to 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) for electrophoresis, the protein were then wet-transferred to polyvinylidene difuoride membrane (Merck Millipore) according to standard procedures. After blocking by 5% non-fat dry milk in TBS-t, the membranes were cut into pieces (referred to molecular weighs as preliminary experiment) and incubated with primary antibodies of anti-endothelial nitric oxide synthases (anti-eNOS) (1:1000, Abcam), anti-a-smooth muscle actin (anti-α-SMA) (1:1000, Abcam), and anti-androgen receptor (anti-AR) (1:1000, Abcam) for 24 h (at 4℃). The secondary antibody of β-Actin (1:200, Zen BioScience Co., Ltd. Chengdu, Sichuan Province, China) was incubated after membranes were washed. The densitometry of protein band was collected by Bio-Rad ChemiDoc MP (Bio-Rad, Berkeley, CA, USA) and its intensities were quantified by Image J sofware (National Institute of Health, Bethesda, MD, USA).

LOX activity

Activity of LOX protein was determined by Amplite™ Fluorimetric LOX assay kit (AAT Bioquest Inc., Sunnyvale, CA, USA) as previous described15,16,34,35. Briefly, the proximal corpus cavernosum was finely snipped and homogenized in PBS (at 4 °C) and centrifuged at 10000g for 30 min to obtain supernatants. After standard procedures according the manufacturer’s instruction, the fluorescence was recorded using BioTek Synergy Mx (BioTek Instruments Co., Ltd., Winooski, VT, USA) with excitation and emission wavelengths at 560 and 590 nm, respectively. The activity of LOX protein was normalized and expressed as RFUs/ug protein.

Statistical analyses

All results were shown as mean ± SD and analyzed by GraphPad Prism 5.0 (GraphPad Sofware, San Diego, CA, USA). For statistical differences among multiple groups, one-way ANOVA analysis was used and followed by Tukey’s test to compare all pairs of columns. Student’s t-test was performed to obtain p value for some groups while a p < 0.05 was considered significant.

Results

Primary and final body weight

As was shown, no significant difference was found for rats’ primary and final body weight (p > 0.05). Although HCG, HCG + VED, and Anti-LOX + HCG + VED dramatically decreased bilateral testicular weight when compared with control, Anti-LOX, VED, and Anti-LOX + VED (p < 0.05), no other difference was found (Fig. S1).

Penile length

All experimental rats showed significantly longer penis than control group (31.00 ± 1.32 mm). Specifically, Anti-LOX (35.58 ± 0.19 mm), HCG (33.33 ± 1.21 mm), VED (34.75 ± 0.85 mm), Anti-LOX + VED (38.92 ± 0.89 mm), HCG + VED (34.17 ± 0.80 mm), and Anti-LOX + HCG + VED (37.92 ± 0.84 mm) dramatically lengthened penis (p < 0.05) by 15% (4.58 mm), 8% (2.33 mm), 12% (3.75 mm), 26% (7.92 mm), 10% (3.17 mm), and 22% (6.92 mm), respectively. Interestingly, Anti-LOX + VED and Anti-LOX + HCG + VED presented the longest penises which were longer than the other five groups (p < 0.05), however, no significant difference was found between these two groups (p > 0.05). Moreover, HCG showed a similar penile length with VED (p > 0.05) but was significantly shorter than Anti-LOX (p < 0.05), while HCG combined with VED (HCG + VED) could not lengthen penis than Anti-LOX or VED group (p > 0.05) (Fig. 1, Tables 1, 2).

Figure 1.

Figure 1

Open in a new tab

Representative images of penile length and statistical analysis of penile size. Penile length were measured after a unified VED aspiration (− 300 mmHg for 5 min for twice, with 2 min interval). * < 0.05, ** < 0.01, *** < 0.001.

Table 1.

Data collection.

Control Anti-LOX HCG VED Anti-LOX + VED HCG + VED Anti-LOX + HCG + VED p

Primary

weight (g)

 132.17 ± 1.77 131.67 ± 1.25 132.50 ± 2.63 132.00 ± 1.83 136.67 ± 3.45 133.33 ± 2.36 134.50 ± 5.44 0.1292
Final weight (g) 264.67 ± 12.41 269.17 ± 11.54 268.50 ± 6.65 258.50 ± 12.61 253.17 ± 7.73 249.33 ± 18.94 246.33 ± 9.66 0.0185
Testicular weight (g) 16.05 ± 1.00 15.66 ± 0.60 11.83 ± 2.26 15.95 ± 1.39 16.35 ± 0.73 11.08 ± 2.24 9.93 ± 2.68  < 0.0001
Penile length (mm) 31.00 ± 1.32 35.58 ± 0.19 33.33 ± 1.21 34.75 ± 0.85 38.92 ± 0.89 34.17 ± 0.80 37.92 ± 0.84  < 0.0001
Exposed penile length (mm) 28.08 ± 0.53 30.50 ± 0.65 28.83 ± 0.69 30.75 ± 0.25 33.42 ± 0.89 31.17 ± 1.55 33.25 ± 0.80  < 0.0001
ICP 63.45 ± 14.70 71.89 ± 5.11 61.21 ± 8.31 79.61 ± 23.17 82.54 ± 18.61 68.06 ± 11.44 77.02 ± 12.33 0.1824
MAP 114.21 ± 10.48 111.87 ± 12.18 121.70 ± 8.40 130.75 ± 12.44 125.31 ± 24.69 118.00 ± 11.26 114.06 ± 18.32 0.4036
ICP/MAP 0.56 ± 0.12 0.65 ± 0.06 0.51 ± 0.08 0.60 ± 0.16 0.65 ± 0.06 0.58 ± 0.05 0.68 ± 0.04 0.0540
Open in a new tab

Table 2.

Penile length comparison in relative and percentage value [(Longer-Shorter)/Shorter].

Penile length Control Anti-LOX HCG VED Anti-LOX + VED HCG + VED
Anti-LOX (mm, %) 4.58 (15%) – – – – –
HCG (mm, %) 2.33 (8%) 2.25 (7%) – – – –
VED (mm, %) 3.75 (12%) 0.83 (2%) 1.42 (4%) – – –
Anti-LOX + VED (mm, %) 7.92 (26%) 3.33 (9%) 5.58 (17%) 4.17 (12%) – –
HCG + VED (mm, %) 3.17 (10%) 1.42 (4%) 0.83 (2%) 0.58 (2%) 4.75 (14%) –
Anti-LOX + HCG + VED (mm, %) 6.92 (22%) 2.33 (7%) 4.58 (14%) 3.17 (9%) 1.0 (3%) 3.75 (11%)
Open in a new tab

Exposed penile length

A similar trend was found for exposed penile length when compared with control group (28.08 ± 0.53 mm). That Anti-LOX (30.50 ± 0.65 mm), HCG (28.83 ± 0.69 mm), VED (30.75 ± 0.25 mm), Anti-LOX + VED (33.42 ± 0.89 mm), HCG + VED (31.17 ± 1.55 mm), and Anti-LOX + HCG + VED (33.25 ± 0.80 mm) significantly increased exposed length (p < 0.05) by 9% (2.42 mm), 3% (0.75 mm), 9% (2.67 mm), 19% (5.33 mm), 11% (3.08 mm), and 18% (5.17 mm), respectively. Exposed penile length in HCG group was still similar with VED (p > 0.05) but significantly shorter than Anti-LOX (p < 0.05), while HCG + VED also showed similar exposed length with Anti-LOX or VED group (p > 0.05). Finally, there was no significant difference for exposed penile size between Anti-LOX + VED and Anti-LOX + HCG + VED groups (p > 0.05) (Fig. 2, Tables 1, 3).

Figure 2.

Figure 2

Open in a new tab

Representative images of exposed penile length and statistical analysis of exposed size. * < 0.05, ** < 0.01, *** < 0.001.

Table 3.

Exposed penile length comparison in relative and percentage value [(Longer-Shorter)/Shorter].

Exposed penile length Control Anti-LOX HCG VED Anti-LOX + VED HCG + VED
Anti-LOX (mm, %) 2.42 (9%) – – – – –
HCG (mm, %) 0.75 (3%) 2.42 (9%) – – – –
VED (mm, %) 2.67 (9%) 0.25 (1%) 2.67 (9%) – – –
Anti-LOX + VED (mm, %) 5.33 (19%) 2.92 (10%) 5.33 (19%) 2.67 (9%) – –
HCG + VED (mm, %) 3.08 (11%) 0.67 (2%) 3.08 (11%) 0.42 (1%) 2.25 (7%) –
Anti-LOX + HCG + VED (mm, %) 5.17 (18%) 2.75 (9%) 5.17 (18%) 2.50 (8%) 0.17 (1%) 2.08 (7%)
Open in a new tab

Erectile function assessment: ICP and ICP/MAP ratio

Although Anti-LOX, VED, Anti-LOX + VED, HCG + VED, and Anti-LOX + HCG + VED presented slightly higher ICP and ICP/MAP ratio than control and HCG groups, no significant difference was found (p > 0.05). The MAP was basically similar among the seven groups (p > 0.05) (Fig. 3, Table 1).

Figure 3.

Figure 3

Open in a new tab

Androgen supplement combined with Anti-LOX + VED had no impact on normal erectile function, whether alone or in combination. (A) Representative images of maximum ICP under cavernous nerve stimulation. (B) Statistical analysis of ICP. (C) Statistical analysis of MAP. (D) Statistical analysis of ICP/MAP ratio.

Erectile function related biomarker: eNOS and α-SMA

As two classical molecular biomarker for erectile function assessment, eNOS and α-SMA were all similar among the seven groups, indicating penile erectile function was not impaired by Anti-LOX, HCG, or VED, whether alone or in combination (p < 0.05) (Fig. 4).

Figure 4.

Figure 4

Open in a new tab

(A, and B) Statistical analysis of eNOS and α-SMA protein expression. (C) Representative images of eNOS and α-SMA expression. (D): Statistical analysis of LOX activity. * < 0.05, ** < 0.01, *** < 0.001.

LOX activity

As was shown, LOX activity in control group was the greatest and significantly higher than control, Anti-LOX, VED, Anti-LOX + VED, HCG + VED, and Anti-LOX + HCG + VED groups (p < 0.05). While VED also revealed higher LOX activity than Anti-LOX, Anti-LOX + VED, HCG + VED, and Anti-LOX + HCG + VED groups (p < 0.05) (Fig. 4).

Hormone and AR level

For HCG concentration, the HCG, VED, HCG + VED, Anti-LOX + HCG + VED groups were significantly higher than control group (p < 0.05), no other significantly difference was found among other groups (p > 0.05) (Fig. 5).

Figure 5.

Figure 5

Open in a new tab

(A, B, and C) Statistical analysis of HCG, testosterone, and dihydrotestosterone, respectively. (D and E): Statistical analysis of androgen receptor (AR) protein expression and representative WB images. * < 0.05, ** < 0.01, *** < 0.001.

For testosterone level, HCG group was significantly higher than control, Anti-LOX, and Anti-LOX + VED groups (p < 0.05). Anti-LOX + HCG + VED group showed increased testosterone concentration that control, Anti-LOX, and Anti-LOX + VED groups (p < 0.05). Moreover, VED and HCG + VED also revealed more testosterone level than Anti-LOX group (p < 0.05) (Fig. 5).

As dihydrotestosterone secretion, HCG group presented higher concentration than control, Anti-LOX, VED, Anti-LOX + VED, HCG + VED, and Anti-LOX + HCG + VED groups (p < 0.05). While the HCG + VED and Anti-LOX + HCG + VED all demonstrated more dihydrotestosterone levels than control, Anti-LOX and Anti-LOX + VED groups (p < 0.05) (Fig. 5).

The WB analysis finally found that AR expression in HCG groups was the highest and significantly increased than the other six groups (p < 0.05), however, no significantly difference was found among other groups (p < 0.05) (Fig. 5).

Discussion

Just like women pursue a bigger breast, men always desire a larger penis not only to impress partners but also to improve self-esteems1,3. Considering the huge personal requirements, more authors suggested to reappraise phalloplasties as an esthetic plastic surgery rather than reconstruction surgery4. However, the phalloplasties are controversial6 and experimental1,5 as the poorly standardized indications and inconsistent surgical methods5,6. So, it will be interesting and necessary to explore new strategies to lengthen penis.

We know that penile tunica albuginea which mainly composed by thick collagen bundles and some elastic fibers determines penile size during tumescence13–16. As an extracellular copper-dependent monoamine oxidase, Lysyl oxidase (LOX) catalyzes the crosslinking of collagen and elastin proteins into insoluble mature fibers to contribute tensile strength of collagen fiber and elasticity of elastin fiber15,16,34,36–38. Our previous study found that inhibiting LOX activity (Anti-LOX) promoted tunica albuginea remodeling by reducing collagen crosslinking, which finally increased penile length by 10.54% for adult rats, this effect achieved 17.71% when Anti-LOX was combined to a mechanical force from VED (Anti-LOX + VED)15. The lengthening effect was more obvious for pubertal rats, that Anti-LOX and Anti-LOX + VED significantly promoted penile length by 10.79% and 19.84%, respectively16.

Similar results were found for pubertal rats in this study, that Anti-LOX and Anti-LOX + VED lengthened penis by 15% and 26%, respectively. We speculated that this final penile length was measured under a VED pressure at − 300 mmHg, thus the size was longer than previous pubertal rats which measured at − 200 mmHg (10.79% and 19.84%)16. We further confirmed the lengthening effect by measuring exposed penile size, that Anti-LOX and Anti-LOX + VED increased length by 9% and 19%, respectively. Moreover, LOX activity in Anti-LOX, Anti-LOX + VED, and Anti-LOX + HCG + VED groups were all inhibited than control group. Combined with our previous researches15,16, we concluded the penile length was improved by remodeling tunica albuginea.

Testosterone is indispensable for penile development11,19,39,40 and androgen-dependent growth is responsible for 70–75% of adult penile length19,41,42. It is reported that testosterone level transient rises in the first 4–6 months after birth and then stabilizes less than 25 ng/dL during infancy and childhood, while penis only grows to 3 cm before 11 years old9. The activation of hypothalamic-pituitary-testicular axis in puberty induces expression of androgen receptor (AR) and stimulates secretion of testosterone and DHT9,43,44, which finally lead the penile growth spurt9,43,45. Disruption of androgen pathway thus inevitably attenuates penile growth and leads congenital micropenis, which affects up to 0.7% of newborn males39. Considering its critically role on penile development, testosterone supplement has been proven to improve penile growth and androgen replacement was recommended for hypogonadotropic hypogonadal micropenis since the 1970s9,12,19,21,22, although still accompanied with some controversy.

As the only FDA approved non-testosterone compounds for testosterone deficiency23, HCG stimulates endogenous testosterone production23 without impairing spermatogenesis23,46. We thus selected HCG rather than testosterone supplement which found that HCG administration (100 mg/kg twice per week for 1 month) significantly elevated testosterone and dihydrotestosterone levels, which was constant with previous studies23,47,48. For adolescent micropenis, Rajendra et al. revealed that HCG (1500–2000 IU once per week for 6 weeks) increased stretched penile length from 15.54 to 37.18 mm, while testosterone (25 mg once a month for 3 months) lengthened it from 26.42 to 64.28 mm49. In this study, we demonstrated that HCG significantly lengthened penis by 8%, however, no difference was observed for exposed penile size (3%). Some researchers also proved that postnatal testosterone therapy only advanced penile growth rather than improved the final length17, while others even claimed testosterone exposure in puberty accelerated AR loss and compromised eventual penile length in adulthood15,50–54. Authors inferred that androgen determined penile development in specific “masculinisation programming window” (MPW) while subnormal androgen could not be reversed by later supplement17,19. Moreover, penile growth involved not only androgen-dependent processes but also some independent procedures17,19,55 that 6/13 individual steps for human penile development and 5/11 for mice were reported to be androgen-independent55, while these nonandrogenic hormones like thyroxin, glucocorticoids or growth hormone might not be corrected simply by testosterone administration56. In conclusion, androgen replacement was not recommended to lengthen penis for healthy male alone considering the controversial effects and accompanied complications50,51.

Even though, we still explored whether HCG supplement synergized with Anti-LOX + VED could create miracle and promote penile growth, considering their respectively essential roles in penile development. As a result, although Anti-LOX + HCG + VED significantly lengthened penis by 22%, it was less effective than Anti-LOX + VED (26%), while the exposed penile length in Anti-LOX + HCG + VED (18%) was also shorter than Anti-LOX + VED (19%). These suggested that HCG supplement did not cooperate with Anti-LOX + VED to promote penile growth.

Ma et al.19 has reported that testosterone induced AR expression to dose-dependent stimulate penile growth. Although we found HCG increased AR level, some inconsistent conclusions have also been observed19,57–60. For instance, Gonzalez-Cadavid et al. found that androgen improved AR mRNA level in rat penile smooth-muscle cells19,59 but Takane et al.58 shown that DHT declined it, while Ma et al. claimed that neither testosterone nor DHT was the major factor to physiologically down-regulate AR in corpora cavernosa19,57. Moreover, Baskin et al. demonstrated that AR positive cells in human fetal penis was similar among normal, castrate, and super testosterone hosts, while they concluded that testosterone might regulated penile growth by extracellular stromal expansion53. As the limited value of testosterone on penile lengthening, we did not further analyze why HCG + VED and Anti-LOX + HCG + VED did not improve AR level.

What’s more, VED and HCG + VED lengthened penis by 12% and 10%, respectively; while increased exposed penile size by 9% and 11%, respectively. These proved that HCG replacement combined a VED force did not promote penile growth, suggesting androgen was not an effective supplement for the “first line” non-invasive penile lengthening technique9. Finally, Anti-LOX, HCG, and VED did not increase or decrease ICP and ICP/MAP ratio, neither alone nor in combination. Meanwhile they did not improve or deteriorate the levels of eNOS and α-SMA, indicating these procedures had no impacts on erectile function.

Even though, our study has several limitations. Firstly, androgen was essential for penile development19,39,41,42, meanwhile we previous demonstrated Anti-LOX + VED lengthened penis by remodeling tunica albuginea15,16. We thus explored whether HCG supplement synergized with Anti-LOX + VED to promote penile growth by accelerating tunica albuginea. However, our negative results suggested the simply combination might not achieve an effect of “1 + 1 = 2”. Secondly, androgen therapy was recommended to improve penile length for micropenis9,12,15,19,21,22 but not for normal individuals, more attention should be paid to clarify the unclear underlying mechanism. Finally, although we tried to explore new procedures to lengthen penis, intensive psychosexual counselling was still primary recommended before some safe and effective procedures were demonstrated.

Conclusion

We confirmed that Anti-LOX promoted penile growth, especially when combined with a VED force. Although HCG administration slightly lengthened penis by stimulating testosterone and dihydrotestosterone secretion, the underlying mechanism was not clarified. Moreover, HCG supplement did not synergize with Anti-LOX + VED to accelerate tunica albuginea remodeling nor facilitate penile growth, although they had no impact on erectile function.

Supplementary Information

Supplementary Information 1. (29.2KB, xlsx)
Supplementary Information 2. (348.6KB, pdf)
Supplementary Information 3. (10.2MB, pdf)
Supplementary Information 4. (8.3MB, pdf)
Supplementary Figure S1. (3.1MB, tif)

Acknowledgements

This manuscript was funded by National Nature Science Foundation of China (No. 82060276), the Science and Technology Department of Guizhou Province (QianKeHeJiChu-ZK[2021]YiBan382), and the Sichuan Province Science and Technology Innovation Seedling Project (2021039).

Author contributions

T.L., Y.T.J., and Q.L.Z. carried out the experiments. P.C., J.H.C., G.S.D., and L.L. contributed to the statistical analysis, interpretation of data, and the manuscript preparation. Y.T.J. and K.H.J. participated in the article screening, experiment design, and critically revising the manuscript. T.L. and K.H.J. conceived of this study and supervised the experiments and the manuscript drafting. All authors read and approved the final manuscript.

Data availability

All data generated or analysed during this study are included in this published article [and its supplementary information files.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Tao Li and Yuan Tian.

Contributor Information

Yiting Jiang, Email: 327265020@qq.com.

Kehua Jiang, Email: tjjkh@sina.com.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-023-38888-y.

References

  • 1.Vardi Y. Is penile enlargement an ethical procedure for patients with a normal-sized penis? Eur. Urol. 2006;49:609–611. doi: 10.1016/j.eururo.2005.12.053. [DOI] [PubMed] [Google Scholar]
  • 2.Park NC. Penile Augmentation. Springer; 2016. pp. 4–5. [Google Scholar]
  • 3.Nugteren HM, et al. Penile enlargement: From medication to surgery. J. Sex Marital. Ther. 2010;36:118–123. doi: 10.1080/00926230903554453. [DOI] [PubMed] [Google Scholar]
  • 4.Colombo F, Casarico A. Penile enlargement. Curr. Opin. Urol. 2008;18:583–588. doi: 10.1097/MOU.0b013e32830fe427. [DOI] [PubMed] [Google Scholar]
  • 5.Ghanem H, Glina S, Assalian P, Buvat J. Position paper: Management of men complaining of a small penis despite an actually normal size. J. Sex Med. 2013;10:294–303. doi: 10.1111/j.1743-6109.2012.02725.x. [DOI] [PubMed] [Google Scholar]
  • 6.Oderda M, Gontero P. Non-invasive methods of penile lengthening: Fact or fiction? BJU Int. 2011;107:1278–1282. doi: 10.1111/j.1464-410X.2010.09647.x. [DOI] [PubMed] [Google Scholar]
  • 7.Lever J, Frederick DA, Peplau LA. Does size matter? Men’s and women’s views on penis size across the lifespan. Psychol. Men Masculin. 2006;7:129–143. doi: 10.1037/1524-9220.7.3.129. [DOI] [Google Scholar]
  • 8.Francesco Ciancio G, Lo Russo A, Innocenti AP, Parisi D, Mondaini N. Penile length is a very important factor for cosmesis, function and psychosexual development in patients affected by hypospadias: Results from a long-term longitudinal cohort study. Int. J. Immunopathol. Pharmacol. 2015;28(3):421–425. doi: 10.1177/0394632015576857. [DOI] [PubMed] [Google Scholar]
  • 9.Kayes O, Shabbir M, Ralph D, Minhas S. Therapeutic strategies for patients with micropenis or penile dysmorphic disorder. Nat. Rev. Urol. 2012;9:499–507. doi: 10.1038/nrurol.2012.150. [DOI] [PubMed] [Google Scholar]
  • 10.Rezakhaniha S, Rezakhaniha B, Siroosbakht S. Which of the anthropometric parameters and hormonal variables in prepubertal children are correlated to true micropenis? Iran J Pediatr. 2021 doi: 10.5812/ijp.108534. [DOI] [Google Scholar]
  • 11.Rezakhaniha S, Rezakhaniha B, Aarabi N, Siroosbakht S. Is It Necessary to Weight Loss in Obese Boys with Small Penile Length? A Case-Control Study. J. Compr. Pediatr. 2020 doi: 10.5812/compreped.107272. [DOI] [Google Scholar]
  • 12.Bin-Abbas B, Conte FA, Grumbach MM, Kaplan SL. Congenital hypogonadotropic hypogonadism and micropenis: Effect of testosterone treatment on adult penile size why sex reversal is not indicated. J. Pediatr. 1999;134:579–583. doi: 10.1016/s0022-3476(99)70244-1. [DOI] [PubMed] [Google Scholar]
  • 13.Hsu GL, et al. The distribution of elastic fibrous elements within the human penis. Br. J. Urol. 1994;73:566–571. doi: 10.1111/j.1464-410X.1994.tb07645.x. [DOI] [PubMed] [Google Scholar]
  • 14.Akkus E, et al. Structural alterations in the tunica albuginea of the penis: Impact of Peyronie’s disease, ageing and impotence. Br. J. Urol. 1997;79:47–53. doi: 10.1046/j.1464-410X.1997.26511.x. [DOI] [PubMed] [Google Scholar]
  • 15.Li T, et al. Anti-lysyl oxidase combined with a vacuum device induces penile lengthening by remodeling the tunica albuginea. Asian J. Androl. 2020;22:485–492. doi: 10.4103/aja.aja_120_19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Li T, Fu F, Wu C, Qin F, Yuan J. Characteristics of penile growth in pubertal rats and a non-invasive method to lengthen the penis. Andrology. 2020;8:1884–1894. doi: 10.1111/andr.12845. [DOI] [PubMed] [Google Scholar]
  • 17.Welsh M, MacLeod DJ, Walker M, Smith LB, Sharpe RM. Critical androgen-sensitive periods of rat penis and clitoris development. Int. J. Androl. 2010;33:e144–152. doi: 10.1111/j.1365-2605.2009.00978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Husmann D. Micropenis: An animal model and its human correlates. Adv. Exp. Med. Biol. 2002;511:41–54. doi: 10.1007/978-1-4615-0621-8_4. [DOI] [PubMed] [Google Scholar]
  • 19.Ma YM, et al. Testosterone regulates keratin 33B expression in rat penis growth through androgen receptor signaling. Asian J. Androl. 2014;16:817–823. doi: 10.4103/1008-682x.129935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Tomova A, et al. Growth and development of male external genitalia: A cross-sectional study of 6200 males aged 0 to 19 years. Arch Pediatr. Adolesc. Med. 2010;164:1152–1157. doi: 10.1001/archpediatrics.2010.223. [DOI] [PubMed] [Google Scholar]
  • 21.Choi S, Han S, Kim D, de Lignieres B. Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J. Urol. 1993;150:657–660. doi: 10.1016/s0022-5347(17)35576-3. [DOI] [PubMed] [Google Scholar]
  • 22.Burstein S, Grumbach M, Kaplan S. Early determination of androgen-responsiveness is important in the management of microphallus. Lancet (London, England) 1979;2:983–986. doi: 10.1016/s0140-6736(79)92560-1. [DOI] [PubMed] [Google Scholar]
  • 23.Krzastek S, Smith R. Non-testosterone management of male hypogonadism: An examination of the existing literature. Transl. Androl. Urol. 2020;9:S160–S170. doi: 10.21037/tau.2019.11.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Brasselet C, et al. Collagen and elastin cross-linking: A mechanism of constrictive remodeling after arterial injury. Am. J. Physiol. Heart Circ. Physiol. 2005 doi: 10.1152/ajpheart.00410.2005.-Constrictive. [DOI] [PubMed] [Google Scholar]
  • 25.Mercier N, Kakou A, Challande P, Lacolley P, Osborne-Pellegrin M. Comparison of the effects of semicarbazide and beta-aminopropionitrile on the arterial extracellular matrix in the Brown Norway rat. Toxicol. Appl. Pharmacol. 2009;239:258–267. doi: 10.1016/j.taap.2009.06.005. [DOI] [PubMed] [Google Scholar]
  • 26.Tamunopriye J, Abiola OO. Human chorionic gonadotrophin (HCG) stimulation test and testosterone response in children with micropenis. Pediatr. Endocrinol. Rev. 2014;12:42–45. [PubMed] [Google Scholar]
  • 27.Savas C, Ozguner M, Ozguner F, Delibas N. The effects of human chorionic gonadotropin treatment on the contralateral side in unilateral testicular torsion. Int. Urol. Nephrol. 2003;35:237–245. doi: 10.1023/B:UROL.0000020288.58686.5b. [DOI] [PubMed] [Google Scholar]
  • 28.Kolon TF, Miller OF. Comparison of single versus multiple dose regimens for the human chorionic gonadotropin stimulatory test. J. Urol. 2001;166:1451–1454. doi: 10.1016/S0022-5347(05)65807-7. [DOI] [PubMed] [Google Scholar]
  • 29.Yuan J, et al. Molecular mechanisms of vacuum therapy in penile rehabilitation: A novel animal study. Eur. Urol. 2010;58:773–780. doi: 10.1016/j.eururo.2010.07.005. [DOI] [PubMed] [Google Scholar]
  • 30.Ozbey H, Temiz A, Salman T. A simple method for measuring penile length in newborns and infants. BJU Int. 1999;84:1093–1094. doi: 10.1046/j.1464-410x.1999.00366.x. [DOI] [PubMed] [Google Scholar]
  • 31.Li J, et al. Reduction in Peyronie’s-like plaque size using a vacuum erection device in a rat model of Peyronie’s disease via the TGF-beta/SMAD signalling pathway. Andrologia. 2018;50:e13051. doi: 10.1111/and.13051. [DOI] [PubMed] [Google Scholar]
  • 32.Li J, et al. Isoflurane inhalation anesthesia should be a new requirement in intracavernosal pressure detection-the gold standard of erectile function assessment. Sci. Rep. 2017;7:14949. doi: 10.1038/s41598-017-15020-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Qian SQ, Gao L, Wei Q, Yuan J. Vacuum therapy in penile rehabilitation after radical prostatectomy: Review of hemodynamic and antihypoxic evidence. Asian J. Androl. 2016;18:446–451. doi: 10.4103/1008-682x.159716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Remus EW, et al. The role of lysyl oxidase family members in the stabilization of abdominal aortic aneurysms. Am. J. Physiol. Heart Circ. Physiol. 2012;303:H1067–1075. doi: 10.1152/ajpheart.00217.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.van Boxtel AL, Kamstra JH, Fluitsma DM, Legler J. Dithiocarbamates are teratogenic to developing zebrafish through inhibition of lysyl oxidase activity. Toxicol. Appl. Pharmacol. 2010;244:156–161. doi: 10.1016/j.taap.2009.12.028. [DOI] [PubMed] [Google Scholar]
  • 36.Bruel A, Ortoft G, Oxlund H. Inhibition of cross-links in collagen is associated with reduced stiffness of the aorta in young rats. Atherosclerosis. 1998;140:135–145. doi: 10.1016/S0021-9150(98)00130-0. [DOI] [PubMed] [Google Scholar]
  • 37.López B. Role of lysyl oxidase in myocardial fibrosis: From basic science to clinical aspects. Am. J. Physiol. Heart Circ. Physiol. 2010 doi: 10.1152/ajpheart.00335.2010.-Because. [DOI] [PubMed] [Google Scholar]
  • 38.Maki JM. Inactivation of the lysyl oxidase gene lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation. 2002;106:2503–2509. doi: 10.1161/01.cir.0000038109.84500.1e. [DOI] [PubMed] [Google Scholar]
  • 39.Becker D, et al. Topical dihydrotestosterone to treat micropenis secondary to partial androgen insensitivity syndrome (PAIS) before, during, and after puberty – A case series. J. Pediatr. Endocrinol. Metab. 2016;29:173–177. doi: 10.1515/jpem-2015-0175. [DOI] [PubMed] [Google Scholar]
  • 40.Siroosbakht S, Rezakhaniha S, Rezakhaniha B. Are androstenedione, dihydrotestosterone, thyroid-stimulating hormone, insulin-like growth factor I, and insulin-like growth factor binding protein 3 necessary for isolated micropenis healthy boys' evaluation without any phenotypic abnormalities? A cross-sectional study. Andrologia. 2022;54:e14617. doi: 10.1111/and.14617. [DOI] [PubMed] [Google Scholar]
  • 41.Boas M, et al. Postnatal penile length and growth rate correlate to serum testosterone levels: A longitudinal study of 1962 normal boys. Eur. J. Endocrinol. 2006;154:125–129. doi: 10.1530/eje.1.02066. [DOI] [PubMed] [Google Scholar]
  • 42.Camurdan A, et al. Current stretched penile length: Cross-sectional study of 1040 healthy Turkish children aged 0 to 5 years. Urology. 2007;70:572–575. doi: 10.1016/j.urology.2007.04.051. [DOI] [PubMed] [Google Scholar]
  • 43.Danish R, Lee P, Mazur T, Amrhein J, Migeon C. Micropenis. II. Hypogonadotropic hypogonadism. Johns Hopkins Med. J. 1980;146:177–184. [PubMed] [Google Scholar]
  • 44.Lee P, Danish R, Mazur T, Migeon C. Micropenis. III. Primary hypogonadism, partial androgen insensitivity syndrome, and idiopathic disorders. Johns Hopkins Med. J. 1980;147:175–181. [PubMed] [Google Scholar]
  • 45.Lee P, et al. Micropenis. I. Criteria, etiologies and classification. Johns Hopkins Med. J. 1980;146:156–163. [PubMed] [Google Scholar]
  • 46.MacIndoe J, et al. Testosterone suppression of the HPT axis. J. Investig. Med. 1997;45:441–447. [PubMed] [Google Scholar]
  • 47.Liu P, Wishart S, Handelsman D. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J. Clin. Endocrinol. Metab. 2002;87:3125–3135. doi: 10.1210/jcem.87.7.8630. [DOI] [PubMed] [Google Scholar]
  • 48.Habous M, et al. Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: A short-course randomized study. BJU Int. 2018;122:889–897. doi: 10.1111/bju.14401. [DOI] [PubMed] [Google Scholar]
  • 49.Nerli RB, Guntaka AK, Patne PB, Hiremath MB. Penile growth in response to hormone treatment in children with micropenis. Indian J. Urol. 2013;29:288–291. doi: 10.4103/0970-1591.120107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Husmann D, Cain M. Microphallus: Eventual phallic size is dependent on the timing of androgen administration. J. Urol. 1994;152:734–739. doi: 10.1016/s0022-5347(17)32694-0. [DOI] [PubMed] [Google Scholar]
  • 51.McMahon D, Kramer S, Husmann D. Micropenis: Does early treatment with testosterone do more harm than good? J. Urol. 1995;154:825–829. doi: 10.1097/00005392-199508000-00134. [DOI] [PubMed] [Google Scholar]
  • 52.Oh JK, Im YJ, Park K, Paick JS. Effects of combined growth hormone and testosterone treatments in a rat model of micropenis. Endocr. Connect. 2018 doi: 10.1530/ec-18-0200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Laurence SB, et al. The effect of testosterone on androgen receptors and human penile growth. J. Urol. 1997;158:1113–1118. doi: 10.1016/S0022-5347(01)64400-8. [DOI] [PubMed] [Google Scholar]
  • 54.Sutherland R, et al. The effect of prepubertal androgen exposure on adult penile length. J. Urol. 1996;156:783–787. doi: 10.1097/00005392-199608001-00061. [DOI] [PubMed] [Google Scholar]
  • 55.Cunha GR, et al. Androgen-independent events in penile development in humans and animals. Differentiation. 2019;111:98–114. doi: 10.1016/j.diff.2019.07.005. [DOI] [PubMed] [Google Scholar]
  • 56.Tietjen DN, Uramoto GY, Tindall DJ, Husmann DA. Micropenis in hypogonadotropic hypogonadism: Response of the penile androgen receptor to testosterone treatment. J. Urol. 1998;160:1054–1057. doi: 10.1016/S0022-5347(01)62696-X. [DOI] [PubMed] [Google Scholar]
  • 57.Shen R, et al. Androgens are not major down-regulators of androgen receptor levels during growth of the immature rat penis. J. Steroid Biochem. Mol. Biol. 1996;57:301–313. doi: 10.1016/0960-0760(95)00283-9. [DOI] [PubMed] [Google Scholar]
  • 58.Takane K, George F, Wilson J. Androgen receptor of rat penis is down-regulated by androgen. Am. J. Physiol. 1990;258:E46–50. doi: 10.1152/ajpendo.1990.258.1.E46. [DOI] [PubMed] [Google Scholar]
  • 59.González-Cadavid N, et al. Up-regulation of the levels of androgen receptor and its mRNA by androgens in smooth-muscle cells from rat penis. Mol. Cell Endocrinol. 1993;90:219–229. doi: 10.1016/0303-7207(93)90155-d. [DOI] [PubMed] [Google Scholar]
  • 60.Lin M, Rajfer J, Swerdloff R, González-Cadavid N. Testosterone down-regulates the levels of androgen receptor mRNA in smooth muscle cells from the rat corpora cavernosa via aromatization to estrogens. J. Steroid Biochem. Mol. Biol. 1993;45:333–343. doi: 10.1016/0960-0760(93)90002-e. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information 1. (29.2KB, xlsx)
Supplementary Information 2. (348.6KB, pdf)
Supplementary Information 3. (10.2MB, pdf)
Supplementary Information 4. (8.3MB, pdf)
Supplementary Figure S1. (3.1MB, tif)

Data Availability Statement

All data generated or analysed during this study are included in this published article [and its supplementary information files.

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES